OnKure Therapeutics, Inc.
OKUR
Get informed when a big investor buys or sells
+ FollowMarket Cap$60.84M
Close$
Share Statistics
| Market cap | $60.84 Million |
|---|---|
| Enterprise Value | $-104,735,584.00 |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -8.92% |
|---|---|
| Return on Assets | -8.56% |
| Return on Invested Capital | -35.98% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.69 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
$166,667
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$166,667
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Reneo Pharmaceuticals Inc
18 employees
CEO: Nicholas A. Saccomano Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produc...